A Single-arm, Dose-escalating Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetic , and Efficacy of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs MT 027 (Primary) ; MT 027 (Primary)
- Indications Brain metastases; Breast cancer; CNS cancer; Colorectal cancer; Glioma; Lung cancer; Malignant melanoma; Meningeal carcinomatosis; Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Suzhou Maximum Bio-tech
- 25 Dec 2024 New trial record